Skip to main content
Evidence Snapshot

Thrombopoietin receptor

CHEMBL1864 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1864
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thrombopoietin receptor as ChEMBL target CHEMBL1864, mapped to UniProt P40238. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thrombopoietin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1864
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P40238
Thrombopoietin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Thrombopoietin receptor matters

As of 2026-09-13

Thrombopoietin receptor is reviewed as Thrombopoietin receptor (UniProt P40238); Thrombopoietin receptor shows approved-linked disease relevance led by Thrombocytopenia. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 371 compounds, and 23 assays, with lead potency reaching pChEMBL 8.5.

Disease context
Thrombocytopenia

Thrombopoietin receptor shows approved-linked disease relevance led by Thrombocytopenia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AVATROMBOPAG, AVATROMBOPAG MALEATE, ELTROMBOPAG CHOLINE.

Start review with Thrombocytopenia because it currently carries approved-linked support. Linked drugs include AVATROMBOPAG, AVATROMBOPAG MALEATE, ELTROMBOPAG CHOLINE, ELTROMBOPAG OLAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 371 compounds, and 23 assays for this target. The dominant activity type is EC50. CHEMBL1257604 is the current potency anchor at pChEMBL 8.5.

Use CHEMBL1257604 as the tractability anchor when discussing potency (pChEMBL 8.5).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 8.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Thrombopoietin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P40238, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Thrombocytopenia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

371
Total Compounds
23
Total Assays
1
Approved Drugs
EC50: 332.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1257604
 8.5 EC50 —
No preferred name
CHEMBL1257603
 8.2 EC50 —
No preferred name
CHEMBL429295
 8.2 EC50 —
No preferred name
CHEMBL248218
 8.1 EC50 —
No preferred name
CHEMBL455654
 8.0 EC50 —

Approved Drugs

Structure Compound First Approval
ELTROMBOPAG
CHEMBL461101
 2008
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1864